Last reviewed 2026-04-22 · How we verify

AVT04

AVT04 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.

AVT04 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer, Non-squamous non-small cell lung cancer, Metastatic breast cancer.

At a glance

Mechanism of action

AVT04 is a monoclonal antibody that binds to and neutralizes VEGF, a key signaling molecule that promotes the formation of new blood vessels. By blocking VEGF, the drug prevents tumors from developing their own blood supply, thereby inhibiting tumor growth and metastasis. As a biosimilar of Avastin (bevacizumab), it is designed to have comparable efficacy and safety to the reference biologic.

Approved indications

• Metastatic colorectal cancer
• Non-squamous non-small cell lung cancer
• Metastatic breast cancer
• Renal cell carcinoma

Common side effects

• Hypertension
• Proteinuria
• Bleeding/hemorrhage
• Thromboembolic events
• Gastrointestinal perforation
• Fatigue
• Diarrhea

Key clinical trials

• Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis (PHASE3)
• Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AVT04 CI brief — competitive landscape report
• AVT04 updates RSS · CI watch RSS
• Alvotech Swiss AG portfolio CI